Eugene Kennedy
Chief Tech/Sci/R&D Officer at CARISMA THERAPEUTICS, INC.
Net worth: - $ as of 2024-05-30
Eugene Kennedy active positions
| Companies | Position | Start | End |
|---|---|---|---|
| CARISMA THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | 2024-05-01 | - |
Career history of Eugene Kennedy
Former positions of Eugene Kennedy
| Companies | Position | Start | End |
|---|---|---|---|
| GALERA THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | 2022-08-31 | 2023-08-31 |
| LUMOS PHARMA, INC. | Chief Tech/Sci/R&D Officer | 2013-12-31 | 2021-03-05 |
| Thomas Jefferson University | Corporate Officer/Principal | 2005-12-31 | 2013-11-30 |
| Innovative Cellular Therapeutics, Inc. | Chief Tech/Sci/R&D Officer | - | - |
The Hope Funds for Cancer Research
 The Hope Funds for Cancer Research Miscellaneous Commercial ServicesCommercial Services The Hope Funds for Cancer Research provides funds for cancer research. The private company is based in Newport, RI. The company was founded by Leah Rush Cann. | Director/Board Member | - | - |
| LUMOS PHARMA, INC. | Chief Tech/Sci/R&D Officer | 2017-11-13 | - |
Training of Eugene Kennedy
| University of Virginia | Undergraduate Degree |
| Medical College of Virginia | Doctorate Degree |
Statistics
International
| United States | 10 |
Operational
| Chief Tech/Sci/R&D Officer | 5 |
| Undergraduate Degree | 1 |
| Doctorate Degree | 1 |
Sectoral
| Health Technology | 5 |
| Consumer Services | 4 |
| Commercial Services | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Listed companies | 3 |
|---|---|
| LUMOS PHARMA, INC. | Health Technology |
| GALERA THERAPEUTICS, INC. | Health Technology |
| CARISMA THERAPEUTICS, INC. | Health Technology |
| Private companies | 3 |
|---|---|
NewLink Genetics Corp.
 NewLink Genetics Corp. Pharmaceuticals: MajorHealth Technology NewLink Genetics Corp. is a late-stage biopharmaceutical company. It engages in the discovery, development, and commercialization of novel immunotherapeutic products to improve cancer treatment options for patients and physicians. The firm's portfolio includes biologic and small molecule immunotherapy product candidates intended to treat a range of oncology indications. It products include HyperAcute Pancreas, HyperAcute Lung, HyperAcute Melanoma, HyperAcute Imunotherapies, NLG8189, and IDO Pathway Inhibitors. The company was founded by Charles J. Link and Nicholas N. Vahanian on June 4, 1999 and is headquartered in Ames, IA. | Health Technology |
The Hope Funds for Cancer Research
The Hope Funds for Cancer Research Miscellaneous Commercial ServicesCommercial Services The Hope Funds for Cancer Research provides funds for cancer research. The private company is based in Newport, RI. The company was founded by Leah Rush Cann. | Commercial Services |
| Innovative Cellular Therapeutics, Inc. |
- Stock Market
- Insiders
- Eugene Kennedy
- Experience
